Friedenthal Financial Makes New $1.09 Million Investment in Biogen Inc. $BIIB

Friedenthal Financial purchased a new position in Biogen Inc. (NASDAQ:BIIB) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 5,930 shares of the biotechnology company’s stock, valued at approximately $1,087,000.

Other large investors have also made changes to their positions in the company. Empowered Funds LLC raised its stake in Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after purchasing an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of Biogen during the second quarter worth about $216,000. Cerity Partners LLC grew its holdings in shares of Biogen by 15.3% during the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock worth $5,847,000 after buying an additional 6,184 shares in the last quarter. Finally, NewEdge Advisors LLC raised its position in shares of Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock valued at $336,000 after buying an additional 316 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analysts Set New Price Targets

BIIB has been the topic of several recent analyst reports. Canaccord Genuity Group upped their price objective on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. Wedbush boosted their price target on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a report on Thursday, April 30th. HSBC boosted their price target on Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a report on Tuesday, March 17th. Rothschild & Co Redburn raised their price objective on Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Biogen in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Biogen currently has a consensus rating of “Moderate Buy” and a consensus price target of $217.37.

Biogen Stock Performance

NASDAQ:BIIB opened at $199.59 on Thursday. The company has a market cap of $29.47 billion, a P/E ratio of 21.42 and a beta of 0.20. The firm’s 50 day moving average is $192.20 and its two-hundred day moving average is $185.31. Biogen Inc. has a fifty-two week low of $121.05 and a fifty-two week high of $205.97. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts expect that Biogen Inc. will post 13.95 EPS for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.